Work was conducted at the University of Bialystok to study plasma galectins (1, 2 and 12) plus serum and urinary levels of tumor necrosis factor (TNF), endothelin-1 (ET-1) and α1-acid-glycoprotein (α1AGP) in regards to the relationship between psoriasis and its related complications.

Recent findings have suggested GAL-201 from Galimedix Therapeutics Inc. is a robust oral candidate to treat Alzheimer’s disease (AD). GAL-201 binds to the misfolded form of amyloid-β (Aβ) monomers, thus preventing its aggregation and formation of neurotoxic oligomers and protofibrils.

The third day of the AD/PD 2024 conference in Lisbon started with a plenary lecture given by Professor Howard Fillit entitled, “Translating the biology of aging into new therapeutics for Alzheimer’s disease.” Fillit, a recognized neuroscientist and geriatrician, and co-founder of the Alzheimer’s Drug Discovery Foundation (ADDF), pointed to the geroscience hypothesis which postulates that targeting aging processes may result in preventive and therapeutic options for diseases of old age, including Alzheimer’s disease (AD).

Intermittent fasting (IF) consists of fasting and refeeding cycles that cause dramatic changes in the gut microbiome and microbiota-derived metabolites, subsequently affecting immune response.

Patients with multiple sclerosis have an increased prevalence of sleep disorders compared to the general population, with an estimated rate ranging from 25% to 50% and negative impacts on quality of life.

Vascular dementia accounts for the second most common cause of dementia after Alzheimer’s disease.